Market research
VTVT vTv Therapeutics Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 131M
- P/E ratio
- Not available
- Analyst target
- 53.8333
- Dividend yield
- Not available
- Beta
- 0.29
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US9183852048
- Market cap
- 131M
- P/E ratio
- Not available
- Analyst target
- 53.8333
- Dividend yield
- Not available
- Beta
- 0.29
About
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the VTVT discussion.
5 years, 4 months ago
vTv Therapeutics Inc is currently in a long term downtrend where the price is trading 10.6% below its 200 day moving average.
From a valuation standpoint, the stock is 98.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 20.8.
vTv Therapeutics Inc's total revenue sank by 8.4% to $6K since the same quarter in the previous year.
Its net income has increased by 100.1% to $3K since the same quarter in the previous year.
Finally, its free cash flow grew by 62.8% to $-2M since the same quarter in the previous year.
Based on the above factors, vTv Therapeutics Inc gets an overall score of 3/5.